Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avience BiomedicalsNSE:AVIENCE +1.17%18 Cash Ratio is 0.21 as of Mar. 2025, which is 425% above its 10-year median of 0.04. GuruFocus rates NSE:AVIENCE with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 841 Medical Devices & Instruments companies, Avience Biomedicals ranks worse than 83.83% on this metric.
Avience Biomedicals has a Cash Ratio of 0.21. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Avience Biomedicals's Cash Ratio or its related term are showing as below:
NSE:AVIENCE'
s Cash Ratio Range Over the Past 10 Years
Min: 0.02 Med: 0.04 Max: 0.21
Current: 0.21
During the past 3 years, Avience Biomedicals's highest Cash Ratio was 0.21. The lowest was 0.02. And the median was 0.04.
NSE:AVIENCE's Cash Ratio is ranked worse than 83.83% of 841
companies
in the Medical Devices & Instruments industry
Industry Median: 0.97
vs NSE:AVIENCE: 0.21
Avience Biomedicals (NSE:AVIENCE) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Avience Biomedicals Cash Ratio Related Terms
Avience Biomedicals Cash Ratio Historical Data
* Premium members only.
The historical data trend for Avience Biomedicals's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avience Biomedicals Cash Ratio Chart
Avience Biomedicals Annual Data
Trend
Mar23
Mar24
Mar25
Cash Ratio
0.04
0.02
0.21
Avience Biomedicals Semi-Annual Data
Mar23
Mar24
Mar25
Cash Ratio
0.04
0.02
0.21
NSE:AVIENCE vs ABT, SYK, MDT: Cash Ratio Comparison
For the Medical Devices subindustry, Avience Biomedicals's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avience Biomedicals Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Avience Biomedicals's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Avience Biomedicals's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avience Biomedicals (NSE:AVIENCE) has a Cash Ratio of 0.21 as of Mar. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Avience Biomedicals and its competitors. This is 425% above median its historical median of 0.04. Over the past decade, Avience Biomedicals' Cash Ratio has ranged from 0.02 to 0.21. According to the industry distribution chart, Avience Biomedicals ranks #705 out of 841 companies in the Medical Devices & Instruments industry, placing it in the top 83.8%.
Is Avience Biomedicals' Cash Ratio too high?
Avience Biomedicals' current Cash Ratio of 0.21 is 425% above median its 10-year median of 0.04. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 0.21. The Medical Devices & Instruments industry median Cash Ratio is 0.97. Avience Biomedicals' value of 0.21 is 78.4% below this industry median. Based on the distribution chart, Avience Biomedicals ranks #705 out of 841 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Avience Biomedicals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Avience Biomedicals' Cash Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Avience Biomedicals ranks #705 out of 841 companies for Cash Ratio. This places Avience Biomedicals in the lower half of its industry. The industry median Cash Ratio is 0.97. Avience Biomedicals' value of 0.21 is 78.4% below this benchmark. Historically, Avience Biomedicals' own Cash Ratio has ranged from 0.02 to 0.21 over the past decade. While the company's 10-year median is 0.04 vs. the industry median of 0.97, Avience Biomedicals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.97, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avience Biomedicals's current Cash Ratio of 0.21 is 78.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Avience Biomedicals and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avience Biomedicals's current Cash Ratio is 0.21, which is 425% above median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avience Biomedicals stock overvalued right now?
Avience Biomedicals (NSE:AVIENCE) has a current Cash Ratio of 0.21. The current Cash Ratio is 0.21, which is 425% above median its 10-year median of 0.04 and 78.4% below the Medical Devices & Instruments industry median of 0.97. Avience Biomedicals' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Avience Biomedicals (NSE:AVIENCE), the current Cash Ratio is 0.21 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avience Biomedicals Ltd is a medical consumables company focused on the manufacturing of Vitro-Diagnostic (IVD) products and medical devices. Its product offerings include diagnostic solutions used for the detection of diseases, conditions, and infections across laboratory, healthcare, and home-use applications. The company operates in areas including molecular biotechnology, genomics, and diagnostic products, and also provides distribution services for medical technology products in India. Its revenue is generated from Manufactured Goods and Traded Goods and Services, which include the sale of Medical Devices and Consumables.
18GF Score
Get the complete analysis for NSE:AVIENCE
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AVIENCE has been successfully added to your 
